| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-07-12 | Pierre Fabre (France) | opening of new premises | Consumer Health Care | Opening of new premises | ||
| 2017-07-12 | Enterome Bioscience (France) | nomination | Nomination | |||
| 2017-07-12 | Daiichi Sankyo (Japan) Max Planck Innovation (Germany) the Lead Discovery Center (Germany) | new lead compound for the treatment of cancer | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-07-12 | Enterome Bioscience (France) | non-executive director | nomination | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases | Nomination | |
| 2017-07-11 | Poxel (France) | nomination | Metabolic diseases | Nomination | ||
| 2017-07-11 | Enterome Bioscience (France) Nestlé Health Science (Switzerland) Microbiome Diagnostics Partners | inflammatory bowel diseases, liver diseases. | joint-venture agreement | Liver diseases - Hepatic diseases - Inflammatory diseases | Joint-venture agreement | |
| 2017-07-10 | PCI Biotech (Norway) undisclosed top-10 large pharma company | fimaNAc technology (nucleic acid therapeutics delivery) | R&D - research | undisclosed | Research agreement | |
| 2017-07-10 | Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA) | T cell therapies | research | Cancer - Oncology | Research agreement | |
| 2017-07-10 | BioInvent (Sweden) Thrombogenics (Belgium) | TB-403, THR-317 | licensing | Cancer - Oncology - Ophtalmological diseases | Licensing agreement | |
| 2017-07-07 | Relief Therapeutics (Switzerland) | resignation | Resignation | |||
| 2017-07-07 | Immunocore (UK) | construction of new premises | Autoimmune diseases – Cancer - Oncology - Infectious diseases | Construction of new premises | ||
| 2017-07-06 | Novartis (Switzerland) Conatus Pharmaceuticals (USA - CA) | emricasan | NASH (non-alcoholic steatohepatitis) and chronic liver diseases | development - licensing - commercialisation | Hepatic diseases - Liver diseases | Exercise of an option agreement |
| 2017-07-06 | Novartis (Switzerland) Oxford Biomedica (UK) | lentiviral vectors used to generate CTL019 (tisagenlecleucel) and other undisclosed Chimeric Antigen Receptor T cell (CART) products | production - manufacturing | Cancer - Oncology - Technology - Services | Production agreement | |
| 2017-07-06 | Eli Lilly (USA - IN) Purdue University (USA - IN) | pain | collaboration | CNS diseases | Collaboration agreement | |
| 2017-07-05 | Coherus Biosciences (USA - CA) Daiichi Sankyo (Japan) | biosimilar forms of etanercept (CHS-0214 ) and rituximab | development - commercialisation | Development agreement | ||
| 2017-07-05 | Horizon Discovery (UK) | novel transposon-based gene editing technology platform | licensing | Technology - Services | Licensing agreement | |
| 2017-07-04 | Sun Pharmaceutical Industries (India) Samsung BioLogics (Republic of Korea) | tildrakizumab | manufacturing - bioproduction | Production agreement | ||
| 2017-07-04 | Sagetis Biotech (Spain) | member of the scientific advisory board | nomination | Cancer - Oncology - Rare diseases | Nomination | |
| 2017-07-03 | Immunocore (UK) GSK (UK) | multiple novel targets not addressable using antibody-based technologies | undisclosed | research - development - licensing | Cancer - Oncology | Milestone |
| 2017-07-03 | Bayer Healthcare (Germany) | construction of new premises | Veterinary medicine | Construction of new premises |
